Arnout Van Hyftes journey with BioStrand, now a subsidiary of IPA (ImmunoPrecise Antibodies), began in 2019 as a key member of the founding team. He has played a pivotal role in shaping the company's commercial strategies, setting the stage for its remarkable growth, and building a robust infrastructure that forms the very foundation of BioStrand's operations. Arnout oversees the development team, ensuring their seamless coordination and fostering a culture of innovation. His leadership extends to crafting effective sales and marketing strategies, as well as engaging with the market to cultivate meaningful relationships.
Integration of wet lab and in silico
IPA integrates the antibody discovery and characterization process with a pioneering neurosymbolic approach to identify optimal candidates. Through harmonizing knowledge layers with unstructured data our method relies on transparency and enhances precision. The goal is to provide program managers and scientists with a combination of desired functionality and provide patient population specific insights.
AI and Data Sciences Showcase:
ImmunoPrecise is a biotherapeutic research hub leveraging systems biology, multiomics modeling and complex artificial intelligence systems to support its proprietary antibody discovery technologies. Combining an AI driven approach with best-in-class laboratory capabilities creates a powerful synergy that is revolutionizing antibody discovery.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.